Human immunodeficiency virus (HIV) - Specific effector CD8 T cell activity in patients with primary HIV infection

Journal of Infectious Diseases

Volumn 185, Issue 6, 2002, Pages 755-765

  Alter, Galit ^a   Merchant, Alefia ^a   Tsoukas, Christos M ^a   Rouleau, Danielle ^b   LeBlanc, Roger P ^a   Côté, Pierre ^c   Baril, Jean Guy ^c   Thomas, Réjean ^d   Nguyen, Vinh Kim ^a   Sékaly, Rafik Pierre ^e   Routy, Jean Pierre ^a   Bernard, Nicole F ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Clinique du Quartier Latin   (Canada)

^d Clinique Medicale LActuel   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; VIRUS PROTEIN;

ADULT; ARTICLE; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DISEASE ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE FUNCTION; MALE; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE;

ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; HIV; HIV INFECTIONS; HLA-A ANTIGENS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA;

EID: 0037086624     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/339338     Document Type: Article

References (47)

1. Virologic and immunologic events in primary HIV infection
2. Acute human immunodeficiency virus type 1 infection
3. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
4. + T cells with a predominant V beta usage during the primary immune response to HIV
5. + cytotoxic T lymphocytes activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
6. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia
7. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infection of rhesus macaques
8. Quantitation of HIV-specific cytotoxic T lymphocytes and plasma viral load RNA
9. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection: Breadth and specificity of the response and relation to in vivo viral quasispecies in a persons with prolonged infection and low viral load
10. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors
11. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
12. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease
13. + lymphocytes
14. + T cell depletion in simian immunodeficiency virus-infected macaques
15. Analysis of successful immune responses in persons infected with hepatitis C virus
16. + T cells associated with the control of infection
17. + T cell responses associated with control of viremia
18. Immune control of HIV-1 after early treatment of acute infection
19. To kill or to cure: Options in host defense against viral infection
20. + T cells
21. Perforin: Structure and function
22. + cells: Evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms
23. + T cells produce antiviral cytokines but are impaired in cytotoxic function
24. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
25. + T cells during an acute virus infection
26. + T cells
27. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood
28. Cutting edge: Rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma
29. Prevalence of HIV-1 resistant to antiretroviral drugs in individuals newly infected by sexual contact or injecting drug use
30. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and preventive purposes
31. Phototyping: Comprehensive DNA typing for HLA-Am B, C, DRB1, DRB3, DRB4, DRB5, and DQB1 by PCR with 144 primer mixes utilizing sequence-specilic primers (PCR-SSP)
32. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection
33. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
34. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups
35. + T-cell effector activity in HIV primary infection
36. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
37. Substantial differences in specificity in HIV-specific cytotoxic T cells in acute and chronic HIV infection
38. Human cytotoxic T lymphocyte responses in Epstein-Barr virus infection
39. + T cells during primary immune response to Epstein-Barr virus in vivo
40. Tat-specific T lymphocytes select for SIV escape variants during resolution of primary viraemia
41. + T lymphocyte responses are induced during acute hepatitis C virus infection but are nor sustained
42. Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes
43. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
44. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation
45. Lack of strong immune selection pressure by the immunodominant HLA-A*0201 restricted CTL response in chronic HIV-1 infection
46. + T cells in individuals receiving highly active antiretroviral therapy